Onkologie. 2010:4(6):357-361

Clinical stages in patients with multiple neoplasms

Edvard Geryk1, Petr Dítě1, Jan Trna1, Jiří Kozel2, Milan Konečný2
1 Fakultní nemocnice, Brno
2 Geografický ústav Přírodovědecké fakulty MU, Brno

The results based in the Czech Cancer Registry in 1976–2005:

a) Of the 125,262 primary neoplasms (52.1 % males, 47.9 % females) there were registered 37.1 % of early clinical stages in males and

46.6 % in females, 9.3 % of advanced stages in males and 9.5 % in females. Unknown stages prevailed over the other stages until 1994.

The cancers of stage IV prevailed in males during the total period. The most of early stages were in Prague, of advanced stages in Pilsen

region. After exclusion of unknown stages, there were of 54,187 duplicities 63.8 % cases of early stages in males and 71.3 % in females;

18.4 % of advanced stages in males and 15.8 % in women. Of other 10,292 multiplicities there were 16.2 % of early stages in males and

11.7 % in females, 1.6 % of advanced stages in males and 1.2 % in females.

b) Of the 165,050 subsequent neoplasms (54.4 % males, 45.6 % females) – in cases following the primary stages I and II there were registered

21.7 % of early stages in males and 27 % in females, 5 % of advanced stages in males and 6 % in females, – in cases following the

primary stages III and IV there were registered 2.5 % of early stages in males and 3.2 % in females, 1.8 % of the advanced stages in males

and 2.2 % in females.

There were uncommon the number of 12,418 subsequent tumors of advanced stages in men (13.8 % of total 89,796 subsequent ones)

and 10,189 in women (13.5 % of total 75,254 subsequent ones), following the primary cancers of stages III, IV. Between these subsequent

and advanced stages predominated – in males 36.9 % cancers of gastrointestinal and 33.1 % respiratory tract, 10.3 % genital organs, 8.1 %

urinary tract, – in females 37 % cancers of gastrointestinum, 21 % breast, 17.2 % genital organs, 12.8 % respiratory and 4.5 % urinary tract.

It is worrying that of total multiple cases every the seventh gastrointestinal cancer in males and the fifth in females were detected at any

advanced clinical stages after primary cancer.

c) Of 41,161 survived up to October 2007 there were 54.7 % of early stages in males and 58 % in females, 5 % of advanced stages in males

and 5.2 % in females, unknown stages 40.3 % in males and 36.9 % in females. Of 84,101 deaths there were 30 % of early stages in males

and 39.8 % in females, 11 % of advanced stages in males and 12.1 % in females, unknown stages 59 % in males and 48.1 % in females.

The results can be suggested to list the multiple neoplasms and their clinical stages in the annual statistical reports of cancers in the

Czech population.

Keywords: multiple neoplasms, early and advanced clinical stages, their distribution

Published: January 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Geryk E, Dítě P, Trna J, Kozel J, Konečný M. Clinical stages in patients with multiple neoplasms. Onkologie. 2010;4(6):357-361.
Download citation

References

  1. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90(8): 606-611. Go to original source... Go to PubMed...
  2. Muto S, Horie S, Takahashi S, et al. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res 2000; 60(15): 4021-4025.
  3. Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004; 10(9): 2918-2921. Go to original source... Go to PubMed...
  4. Nelson HD, Huffman LH, Fu R, et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005; 143(5): 362-379. Go to original source... Go to PubMed...
  5. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60(2): 183-189. Go to original source... Go to PubMed...
  6. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336(13): 897-904. Go to original source... Go to PubMed...
  7. Socié G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18(2): 348-357. Go to original source... Go to PubMed...
  8. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348(17): 1681-1691. Go to original source... Go to PubMed...
  9. Fairley CK, Sheil AG, McNeil JJ, et al. The risk of anogenital malignancies in dialysis and transplant patients. Clin Nephrol 1994; 41(2): 101-105. Go to PubMed...
  10. Huang J, Walker R, Groome PG, et al. Risk of thyroid carcinoma in a female population after radiotherapy for breast carcinoma. Cancer 2001; 92(6): 1411-1418. Go to original source...
  11. Holland JM, Arsanjani A, Liem BJ, et al. Second malinancies in early stage laryngeal carcinoma patients treated with radiotherapy. J Laryngol Otol 2002; 116(3): 190-193. Go to original source... Go to PubMed...
  12. Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology, 2005; 128: 819-824. Go to original source... Go to PubMed...
  13. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366(9503): 2087-2106. Go to original source... Go to PubMed...
  14. Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6(8): 557-565. Go to original source... Go to PubMed...
  15. Kirova YM, Vilcoq JR, Asselain B, et al. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer 2005; 104(4): 856-863. Go to original source... Go to PubMed...
  16. Rubino C, Shamsaldin A, La MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 2005; 89(3): 277-288. Go to original source... Go to PubMed...
  17. Zablotska LB, Chak A, Das A, et al. Increased risk os squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol 2005; 161(4): 330-337. Go to original source... Go to PubMed...
  18. Valagussa P, Moliterni A, Terenziani M, et al. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 1994; 5(9): 803-808. Go to original source... Go to PubMed...
  19. Kaldor JM, Day NE, Kittelmann B, et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int I Cancer 1995; 63(1): 1-6. Go to original source... Go to PubMed...
  20. Travis, LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin´s disease. J Natl Cancer Inst 2002; 94(3): 182-192. Go to original source... Go to PubMed...
  21. Curtis RE, Freedman DM, Sherman ME, et al. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004; 96(1): 70-74. Go to original source... Go to PubMed...
  22. Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. British Tamoxifen Second Cancer Study Group. J. Natl Cancer Inst 2005; 97(5): 375-384. Go to original source... Go to PubMed...
  23. Konečný M, Geryk E, Kubíček P, kol. Prevalence nádorů v České republice 1989: 2005-2015. PřF MU Brno, 2008; 69: ISBN 978-80-903255-2-4.
  24. Geryk E, Dítě P, kol. Zátěž nádory a jejich multiplicity. Čas. Lék. Čes. 2011; v tisku.
  25. Geryk E, Dítě P. Co mohou naznačit pokročilá klinická stadia u nemocných s vícečetnými novotvary. Sborník přednášek XV. dny prof. Vl. Staška, Praha 9. 4. 2010, 2010: 31-32, ISBN 978-80-87339-02-2.
  26. Geryk E, Dítě P, Pešek M, Kozel J. Následné primární notovary u 125 262 onkologicky nemocných v České republice 1976-2005. Onkologie 2009; 3(3): 181-189.
  27. Geryk E, Dítě P, Kozel J, kol. Nádorové multiplicity u české populace. Čas. Lék. Čes. 2001; 149(4): 178-183.
  28. Geryk E, Dítě P. Sedláková L, kol. Trend vícečetných nemelanomových nádorů kůže z pohledu jejich epidemiologie. Dermatologie pro praxi 2010; 4(1): 5-9.
  29. Geryk E, Dítě P, Kozel J, kol. Vícečetné nádory gastrointestinálního traktu v České republice v letech 1976-2005. Čes Slov Gastroent Hepatol 2010; 64(1): 12-21.
  30. ACS. Cancer Facts & Figures 2009. Atlanta: American Cancer Society, 2009: 1-68.




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.